The short answer
REDEFINE 4 was randomised but open-label: its ClinicalTrials.gov record lists masking as none. Knowing which drug you received can influence adherence, behaviour and adverse event reporting, which matters more for a behaviourally sensitive outcome like body weight than for a hard endpoint.
Key facts
- REDEFINE 4 allocation
- Randomised
- REDEFINE 4 masking
- None (open-label)
- Registration
- NCT06131437
- Randomisation protects
- Comparability at baseline
- Blinding protects
- What happens afterwards
- Most vulnerable outcomes
- Behaviourally influenced ones
Two different protections
Randomisation and blinding do different jobs and are frequently confused. Randomisation makes groups comparable at the start by distributing known and unknown differences by chance. Blinding protects what happens after that: how participants behave, how investigators assess, how adverse events get reported. A trial can have one without the other, and REDEFINE 4 did.
Why weight is a vulnerable endpoint
Body weight responds to behaviour. A participant who knows they received the drug they hoped for may adhere differently, eat differently, or persist through early side effects that would otherwise have caused them to stop. None of that requires anyone to act in bad faith. It is ordinary human response to information, and blinding exists to remove it.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Where it shows up in the numbers
Most visibly in discontinuation, which then propagates into the treatment-policy estimand. If knowledge of assignment affects who stops and when, it affects the estimand that counts everyone regardless of adherence. That is one plausible contributor to the gap between REDEFINE 4's two reported estimands, though a gap would exist in a blinded trial too.
Why it is sometimes unavoidable
Blinding two injectables with different administration schedules, devices and side-effect profiles is difficult. Participants often work out their assignment from the experience regardless of packaging. Running open-label is frequently a practical decision rather than a careless one, which is a reason to note the limitation, not to dismiss the trial.
The pattern across recent incretin evidence
REDEFINE 4 was open-label. The survodutide dose-response trial in Diabetologia carried an open-label semaglutide arm. Where a comparator is unblinded, the comparison is weaker than a fully blinded one, and that qualification belongs beside the numbers rather than in a limitations paragraph nobody reads.
How to check
The ClinicalTrials.gov record states allocation and masking directly. For NCT06131437 it reads randomised, masking none. It takes seconds and it is more reliable than a press release, which will rarely lead with the design limitation.
Frequently asked questions
Was REDEFINE 4 randomised?
Yes, randomised but open-label. Its registry record lists allocation as randomised and masking as none.
Why does blinding matter more for weight than for other endpoints?
Weight responds to behaviour, and knowing your assignment can change adherence, persistence through side effects and reporting.
Does open-label mean the trial is unreliable?
No. It is a real limitation that weakens the comparison, and blinding two different injectables is difficult.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialClinicalTrials.gov · CagriSema compared to tirzepatide (NCT06131437)clinicaltrials.gov
- PubMedBlüher M et al., survodutide dose-response with open-label semaglutide. Diabetologia 2024 (PMID 38095657)pubmed.ncbi.nlm.nih.gov
- PubMedBoisseau W et al., Understanding non-inferiority trials. Neurochirurgie 2026 (PMID 41353860)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Two Answers to the Same QuestionCagriSema pairs GLP-1 with amylin; tirzepatide pairs it with GIP. REDEFINE 4 was effectively the first direct test between those strategies.
- Semaglutide and Liver Disease: What ESSENCE TestedA 1,205-participant Phase 3 in metabolic dysfunction-associated steatohepatitis, published in NEJM in June 2025. What it measured and why liver trials are hard.
- FLOW: A Kidney Outcome Trial, Stopped Early3,533 participants with type 2 diabetes and chronic kidney disease. What FLOW measured, and why it is a harder kind of evidence than a weight trial.
- SELECT: The Trial That Changed What the Class Was For17,604 participants with obesity and cardiovascular disease but no diabetes. Why studying that population specifically was the point.
- The Attribution Problem Running Through Every IndicationHeart, kidney and liver benefits all appear alongside substantial weight reduction. Separating the two is harder than it looks, and mostly has not been done.